RE:RE:89 bio The sale pitch could be we have finalized our discussions with both agencies and have a ready to go program, our innovative approach to find a cure for this unmet condition with growing prevalence affecting millions is unique in a industry where other programs so far have not been successful.Our protocol has been reviewed by leading KOL's and the agencies actually recommended to move it from HIV to general population. We will potentially partner with another company to utilize their expertise and resources in order to increase the odds of getting Tesamorelin approved as maybe not the first but one of the best approved drugs for a fatal condition. The potential revenues for an approved drug will be $$$. Although our intentions are to have the program started by way of collaboration with other interested companies we will certainly won't give it up in case we should proceed with the program ourselves since the financial prospects of a drug curing the condition are great.
I am sure Paul can do a better job than me to sell the program. As reminder there are only 6 phase 3 companies in the space, a combo approach is also very much a possibility. Their NASH phase3 protocol is worth $$ and investors should factor in that value. The job is to to sell it.
qwerty22 wrote:
They have close to $200 mil in bank plus they have active clinical trials.
You should take SPCEO's lead and rightfully position NASH now. There is no sales pitch with NASH. Inevitably critical investors will focus on why thtx is not proceeding alone and that is not a positive conversation to have. 25% increase in cost is not a complete answer, if the opportunity was right for THTX they'd absorb the extra cost, the opportunity isn't right. It would be wasted energy to get into that complex discussion with people.
It's near impossible to guess their chances of success in partnership, the only way to know is go out there and see what the response is and unfortunately we are never going to be given insight into that process.
Even if the company was promotional NASH wouldn't be the program to promote.
scarlet1967 wrote: This phase2b NASH company is currently valued $350M versus THTX's $310M, they only have one program and that's it. I believe the company still needs to go out there and promote their programs including NASH whether they are currently negotiating a partnership or not. Investors need to be educated in order to factor in the value of their now finalized NASH protocol. We have few months before the oncology results will be announced, this is a perfect timing to fill the gap between news by starting the NASH marketing. There is no reason why not now that their negotiations are finalized.
ETNB $16.97 (-0.47%) on Yahoo Finance
https://finance.yahoo.com/quote/ETNB?p=ETNB